ConexiantFDA Updates Lumateperone Label with Relapse-Prevention Data

📋 Regulatory Action / Label Change

The FDA approved a supplemental NDA for lumateperone (CAPLYTA) adding Phase 3 maintenance data to the schizophrenia label. The update positions lumateperone with formally documented relapse-prevention evidence alongside its existing acute-treatment indication.

Professional Impact

• The randomized withdrawal trial showed a 63% reduction in relapse risk (HR 0.37) versus placebo over 26 weeks, with statistical significance for time to relapse (p=0.0002).
• At six months, 84% of lumateperone-treated patients remained relapse-free, compared with the placebo arm where discontinuations accumulated more rapidly.
• The 12-month open-label extension reported a mean weight change of –2.05 kg with stable metabolic parameters and no clinically relevant prolactin elevation.
• Headache was the most common treatment-related adverse event, occurring at roughly twice the placebo rate; no new safety signals emerged.

Action Items

• Review the updated label before next maintenance visit with patients on lumateperone.
• Document rationale for continuing versus switching therapy in stable patients.
• Monitor weight and metabolic parameters consistent with long-term antipsychotic prescribing.
• Update patient counseling on relapse-risk reduction expectations.

More in Schizophrenia